Log in

ETR:GXIGerresheimer Stock Price, Forecast & News

€87.85
+1.35 (+1.56 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
€86.60
Now: €87.85
€88.15
50-Day Range
€70.60
MA: €77.56
€86.50
52-Week Range
€50.65
Now: €87.85
€85.35
Volume79,492 shs
Average Volume140,925 shs
Market Capitalization$2.76 billion
P/E RatioN/A
Dividend Yield1.48%
BetaN/A
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for diabetes or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
Read More
Gerresheimer logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.92 out of 5 stars


Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-211-618100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.39 billion
Cash Flow€2.95 per share
Book Value€29.47 per share

Profitability

Miscellaneous

Employees9,867
Market Cap$2.76 billion
Next Earnings Date7/14/2020 (Estimated)
OptionableNot Optionable

Receive GXI News and Ratings via Email

Sign-up to receive the latest news and ratings for GXI and its competitors with MarketBeat's FREE daily newsletter.

Gerresheimer (ETR:GXI) Frequently Asked Questions

How has Gerresheimer's stock been impacted by COVID-19 (Coronavirus)?

Gerresheimer's stock was trading at €59.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GXI stock has increased by 47.5% and is now trading at €87.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gerresheimer?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gerresheimer in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Gerresheimer.

When is Gerresheimer's next earnings date?

Gerresheimer is scheduled to release its next quarterly earnings announcement on Tuesday, July 14th 2020. View our earnings forecast for Gerresheimer.

What price target have analysts set for GXI?

9 analysts have issued 12-month price targets for Gerresheimer's stock. Their forecasts range from €50.00 to €92.00. On average, they anticipate Gerresheimer's share price to reach €75.89 in the next year. This suggests that the stock has a possible downside of 13.6%. View analysts' price targets for Gerresheimer.

Has Gerresheimer been receiving favorable news coverage?

Media stories about GXI stock have been trending negative this week, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gerresheimer earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Gerresheimer.

Who are some of Gerresheimer's key competitors?

What other stocks do shareholders of Gerresheimer own?

Who are Gerresheimer's key executives?

Gerresheimer's management team includes the following people:
  • Mr. Dietmar Siemssen, CEO & Member of Management Board (Age 56)
  • Dr. Lukas Burkhardt, Member of Management Board (Age 40)
  • Ms. Katja Schnitzler, Group Director of Bus. Excellence & Continuous Improvement and Member of the Supervisory Board (Age 38)
  • Ms. Severine Camp, Corp. Sr. Director of Investor Relations
  • Mr. Jens Kürten, Group Sr. Director of Communication & Marketing and Press Officer of Corp. Media

What is Gerresheimer's stock symbol?

Gerresheimer trades on the ETR under the ticker symbol "GXI."

What is Gerresheimer's stock price today?

One share of GXI stock can currently be purchased for approximately €87.85.

How big of a company is Gerresheimer?

Gerresheimer has a market capitalization of $2.76 billion and generates $1.39 billion in revenue each year. Gerresheimer employs 9,867 workers across the globe.

What is Gerresheimer's official website?

The official website for Gerresheimer is www.gerresheimer.com.

How can I contact Gerresheimer?

Gerresheimer's mailing address is Klaus-Bungert-Strasse 4, DUESSELDORF, 40468, Germany. The company can be reached via phone at +49-211-618100.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.